Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + gemcitabine + carboplatin in metastatic triple-negative breast cancer
ChiCTR2600117338Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in breast cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Jan 2026; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600117338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117338.